Merck Sharp + Dohme Corp.

Schering Corporation

Merck Sharp + Dohme B.v.

Dendreon Corporation

Schering-plough Corporation

Henry M Vaccaro

Tin-Yau Chan

Anandan Palani

Brian Alexander McKittrick

Robert G Aslanian

Kevin D McCormick

Dong Xiao

Srikanth Venkatraman

Younong Yu

Joey Lee Methot

Phieng Siliphaivanh

Christopher W Boyce

Mariappan Chelliah

Salem Fevrier

Haiyan Pu

Keith A Eagen

William Colby Brown

William J Greenlee

Viyyoor Moopil Girijavallabhan

Ashit K Ganguly

F George Njoroge

James Han Wang

Samuel Chackalamannil

Zhaoning Zhu

Hao Wu

Duane A Burnett

Anil K Saksena

Frank W Bennett

Xianhai Huang

Stephane L Bogen

Ashok Arasappan

Elizabeth M Smith

Alan B Cooper

Hongjun Zhang

Raymond G Lovey

Yan Xia

Jian Liu

Jason M Cox

Kevin X Chen

Yi-Tsung Liu

Odile Esther Levy

John S Debenham

Ronald M Kim

Robert D Mazzola, Jr

Purakkattle J Biju

Patrick A Pinto

Tjeerd Barf

Russell E Pike

Rajan Anand

Xiaolei Gao

Xiao Chen

Charles A Lesburg

Ashwin Umesh Rao

Clare London

Chundao Yang

Unmesh G Shah

Qin Jiang

Christopher Joseph Sinz

Adrianus Petrus Antonius De Man

Marguerita S Lim-Wilby

Shilan Liu

Edwin Jao

Martin C Clasby

Haiyan Wang

Joel M Harris

Allard Kaptein

Yuhua Huang

Sobhana Babu Boga

Chad E Bennett

Jose S Duca

Jun Qin

Ping Lan

Hugh Y Zhu

Chad E Knutson

Elizabeth Helen Kelley

Christiaan Gerardus Johannes Maria Jans

Arthur A Oubrie

Jinping L McCormick

Tejal Parekh

Li Dong

Johannes Bernardus Maria Rewinkel

Hyunjin M Kim

Abdul-Basit Alhassan

Scott Jeffrey Kemp

Pawan Dhondi

Zhongxiang Sun

Bama Santhanam

Wanli Wu

Hong Dong Chu

Jacobus C H M Wijkmans

Jie Wu

Susan Y Tamura

Sylvia Joanna Degrado

Hans C A Raaijmakers

Li Wang

Eugenia Y Kiselgof

Siska Hendrata

Liwu Hong

Xin Yao

Xiaobang Gao

Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders. 

BTK Inhibitors

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included. 

Substituted spiropiperidinyl compounds useful as GPR120 agonists

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

[object Object]

The invention provides certain quinolines and aza-quinolines of the Formula (I), and their pharmaceutically acceptable salts, wherein E, J, J, J, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

The invention relates to fused-imidazoyl compounds of Formula (I): wherein ring A, R, R, R, R, R, R, R, R, R, m and n are as defined herein. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and methods of using the compound of Formula (I) to treat microbial infections. 

Fused-imidazoyl compounds useful as antimicrobial agents

The present invention relates to 3-Heterocyclic Substituted Indole Derivatives, compositions comprising at least one 3-Heterocyclic Substituted Indole Derivative, and methods of using the 3-Heterocyclic Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

3-heterocyclic substituted indole derivatives and methods of use thereof

The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. 

Heterocyclic compounds as factor IXA inhibitors

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Peptides as NS3-serine protease inhibitors of hepatitis C virus

The present invention relates to Azetidinone Derivatives of structural formula 1: and compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.

Azetidinone derivatives and methods of use thereof

Growing community of inventors

South Plainfield, NJ, United States of America

Henry M Vaccaro